A new category of products containing synthetic or highly concentrated 7-hydroxymitragynine (7-OH) has recently emerged in the U.S. marketplace. These products are often marketed alongside traditional kratom but differ significantly in chemistry, potency, manufacturing process, and potential public health risk.

Failure to distinguish between natural kratom products and synthetic 7-OH products may lead to ineffective or misdirected regulation.

Kratom refers to the leaves of Mitragyna speciosa, a tropical tree traditionally used in Southeast Asia.

Natural kratom products typically contain:

• Over 40 naturally occurring alkaloids
• Mitragynine as the dominant compound
• Only trace levels of 7-hydroxymitragynine

Typical natural concentrations:

Traditional kratom products include:

• Powdered leaf
• Capsules
• Crushed Leaf
• Extracts

Synthetic 7-OH products contain isolated or chemically converted 7-hydroxymitragynine.

These products often appear as:

• Tablets
• Gummies
• Drink shots
• Concentrates

Laboratory analyses have identified some products containing extremely high concentrations of 7-OH, sometimes approaching nearly pure alkaloid formulations.

This level of concentration does not occur naturally in kratom leaves.

7-hydroxymitragynine is significantly more potent at opioid receptors than mitragynine.

Research indicates:

• 7-OH can be many times more potent than mitragynine
• Isolating this compound removes the moderating effects of other kratom alkaloids

Natural kratom concerns generally involve:

• Contamination
• Adulteration
• Lack of manufacturing standards

Synthetic 7-OH products introduce additional risks:

• Higher pharmacological potency
• Unknown impurities from chemical conversion
• Lack of long-term safety data

The Controlled Substances Act (21 U.S.C. §811) requires regulators to consider eight factors when evaluating substances.

Applying this framework shows that:

Effective policy should recognize the scientific differences between botanical kratom and synthetic derivatives.

Key recommendations:

1. Establish a regulatory distinction between natural kratom and synthetic 7-OH products

2. Implement product standards for natural kratom, including:

• Contaminant testing
• Alkaloid labeling
• Manufacturing quality requirements

3. Evaluate synthetic 7-OH independently under the Controlled Substances Act framework.

4. Support scientific research on natural kratom pharmacology and safety.

⚠️Natural Kratom vs. 7-OH Policy Analysis in Details for Lawmakers coming soon‼️

Natural kratom and synthetic 7-hydroxymitragynine products represent distinct categories of substances with different pharmacology, manufacturing processes, and risk profiles.

Science-based policy should regulate them separately to ensure appropriate consumer protection while avoiding unintended consequences.

Disclaimer:

This article is provided for educational and informational purposes only and should not be considered legal or medical advice. Kratom regulations may change and can vary by jurisdiction. Readers should verify current laws with their local or state authorities and consult a licensed healthcare or legal professional before using any kratom products.

The information presented above summarizes key points from the Eight-Factor Analysis regarding natural kratom and the abuse potential of synthetic 7-hydroxymitragynine (7-OH) products. This briefing sheet highlights selected findings from the analysis and does not include the full scope of available research. A follow-up article will be published soon outlining additional details and scientific findings referenced in the analysis.

If you are a lawmaker and looking into obtaining a copy of the 8-Factor Analysis on Natural Kratom and the Abuse Potential of 7-OH please contact our Support Team at [email protected].